Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial
Conditions
Interventions
Aprepitant
Palonosetron
+1 more
Locations
1
China
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine
Hanzhou, Zhejiang, China
Start Date
July 1, 2023
Primary Completion Date
July 1, 2028
Completion Date
July 1, 2029
Last Updated
May 3, 2023
NCT04541381
NCT05468034
NCT03137095
NCT07547774
NCT07040891
NCT04852887
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions